The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
This article describes a new partnership between two European based companies for the development of a novel agent, Siramesine, in the treatment of cancer. What makes this interesting is that this is yet another "targeted therapy" for cancer, involving the induction of apoptosis or programmed cell death....
The company claims that Erbitux has shown survival benefit in lung cancer (NSCLC) in the current Phase III trial. how much benefit? what are its implications?
Xeloda has proven equal to infusional 5FU in recent colorectal cancer trial Xeloda is an oral agent versus iv 5FU and is therefore prefered therapy Xeloda has a diffrenet toxicity profile than infusional 5FU
Recent studies demonstrate benefit with picoplatin in HRPCa Other trials have used differnt platinums such as Satraplatin in HRPCa with encouraging results Othe tumors have also benefitted from the newer second/ third generation platinums
CMS recently tried to glut tohe use of ESAs ESAs have had considerable backing in trial results EsAs situation is just a continuation of the reimbursement disaster being established by CMS with indemity plans to follow
Ixabepilone is the first in a new class of antineoplastic agents. This international, randomized, phase II trial assessed two administration schedules of ixabepilone as second-line therapy in patients with non–small-cell lung cancer There may be concern for cytotoxics versus biologics in todays...
Erbitux has promising results in colorectal cancer trials. Erbitux has a future in colorectal cancer. Erbitux has some pending trilas that could explode the drug's popularity. Erbitux may have an advantage over Avastin .
Statins have recent reputation as cancer promoting.
Statins also have demonstrated benefit in treating cancer patients
Statins can be eliminated based on the first issue